Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Bone Marrow Transplantation

• Publication date

  1991-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 1933064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of acute graft-versus-host disease.

  1990cited by this paper
• The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation.

  1990cited by this paper
• A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment.

  1990cited by this paper
• Soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor plasma levels in renal allograft recipients.

  1990cited by this paper
• Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

  1990cited by this paper
• Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.

  1989cited by this paper
• Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].

  1989cited by this paper
• An overview of the use of the monoclonal antibody OKT3 in renal transplantation.

  1988cited by this paper
• T cell activation by monoclonal antibodies: an approach to study principles of immunoregulation.

  1988cited by this paper
• Clinical development of Orthoclone OKT3.

  1987cited by this paper
• Induction of monocyte procoagulant activity with OKT3 antibody.

  1987cited by this paper
• Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

  1986cited by this paper
• Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors.

  1986cited by this paper
• Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience

  1985cited by this paper
• TREATMENT OF ACUTE GRAFT‐VERSUS‐HOST DISEASE WITH MONOCLONAL ANTIBODY OKT3

  1984cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper

• T-2 mycotoxin Induces male germ cell apoptosis by ROS-mediated JNK/p38 MAPK pathway.

  2023cites this paper
• Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD

  2012cites this paper
• Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc− mouse model

  2012cites this paper
• Pathophysiology, prevention, and treatment of acute graft-versus-host disease

  2011cites this paper
• Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins

  2010cites this paper
• Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

  2009cites this paper
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  2009cites this paper
• Current and novel therapies in acute GVHD.

  2008cites this paper
• Novel drugs for the prevention and treatment of acute GVHD.

  2008cites this paper
• Muromonab-CD3 (Orthoclone OKT3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation

  2006cites this paper
• Biologics in the prevention and treatment of graft rejection

  2006cites this paper
• Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies

  2004cites this paper
• Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.

  2002cites this paper
• Pathophysiology and treatment of graft-versus-host disease.

  1999cites this paper
• Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.

  1998cites this paper
• [Gastrointestinal complications in stem cell transplantation].

  1997cites this paper
• UVB-irradiation of human bone marrow: potential for donor specific tolerance.

  1996cites this paper
• Applications of hematopoietic stem cells and gene transfer.

  1996cites this paper
• Effects of ultraviolet-B irradiation on human LAK and NK cytotoxic activity.

  1995cites this paper
• Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.

  1995cites this paper
• ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT‐VERSUS-HOST DISEASE

  1995cites this paper
• Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

  1995cites this paper
• Selected complications of allogeneic bone marrow transplantation.

  1994cites this paper
• The use of OKT3 in recipients of pancreatic, pulmonary, and bone marrow allografts

  1993cites this paper
• Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection

  1993cites this paper
• Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis

  1993cites this paper
• The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.

  1993cites this paper
• Systemic Release of Tumor Necrosis Factor Alpha in Human Allogeneic Bone Marrow Transplantation: Clinical Risk Factors, Prognostic Significance, and Therapeutic Approaches

  1992cites this paper
• Immunosuppression in transplantation.

  1992cites this paper